Skip to content
Stabilitech logo — Advancing vaccine and biopharmaceutical stability with pione...

Stabilitech

Advancing vaccine and biopharmaceutical stability with pioneering formulations.

Founded 2002 Series C Total: $9.00M Biotechnology, Pharmaceutical

General Information

Company Name Stabilitech
Founded Year 2002
Industries Biotechnology, Pharmaceutical
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Stabilitech. To contact Stabilitech, visit stabilitech.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Stabilitech compare?

A PDF of Stabilitech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Stabilitech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Stabilitech

Stabilitech, founded in 2002 by Dr. Jeff Drew, is a privately-owned enterprise based in the London Bioscience Innovation Centre, dedicated to stabilizing sensitive biological molecules, including vaccines and biopharmaceuticals. The company's mission revolves around enhancing the stability of these critical components through proprietary formulation technology. This innovative approach ensures the long-term stability of various thermally sensitive viruses, vaccines, and biopharmaceuticals. Notably, the compositions consist of chemical ingredients already approved for clinical use, either as injectables or listed as Generally Regarded As Safe (GRAS). Stabilitech's strategic focus is on commercializing its technology through partnerships with major pharmaceutical and biotechnology firms, as well as global health organizations. In August 2011, the company secured a significant $3.50M Series C investment.

Stabilitech, founded in 2002 by Dr. Jeff Drew, is a privately-owned enterprise based in the London Bioscience Innovation Centre, dedicated to stabilizing sensitive biological molecules, including vaccines and biopharmaceuticals. The company's mission revolves around enhancing the stability of these critical components through proprietary formulation technology. This innovative approach ensures the long-term stability of various thermally sensitive viruses, vaccines, and biopharmaceuticals. Notably, the compositions consist of chemical ingredients already approved for clinical use, either as injectables or listed as Generally Regarded As Safe (GRAS). Stabilitech's strategic focus is on commercializing its technology through partnerships with major pharmaceutical and biotechnology firms, as well as global health organizations. In August 2011, the company secured a significant $3.50M Series C investment.

Business keywords: biopharmaceuticals, vaccines, stabilization technology, thermally sensitive viruses, formulation technology, biological molecules, drug stability, pharmaceutical partnerships, global health organizations

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $3.50M -
06 Aug 2011
Debt Financing £2.20M -
13 May 2011
Venture Round £3.30M -
12 Mar 2009

Stabilitech Alternatives & Competitors

View All Alternatives
Stabilitech vs

Intensive Vitamin C Treatment to Diminish Wrinkles

Series B
3 employees
Biopharma, Biotechnology
Stabilitech vs

Supply Vaccines to Eliminate Human Diseases

Post-IPO Equity
209 employees
Biotechnology, Health and Wellness
Stabilitech vs

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commerci...

Post-IPO Debt
396 employees
Biotechnology, Health Care

FAQ About Stabilitech

Advancing vaccine and biopharmaceutical stability with pioneering formulations.
Stabilitech was founded in 2002.
Stabilitech operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceuticals, vaccines, stabilization technology and thermally sensitive viruses.
Stabilitech has completed 3 funding rounds, raising a total of $9.00M. The latest funding stage is Series C.
Top alternatives and competitors to Stabilitech include Silk Therapeutics, Inc., SINOVAC BIOTECH LTD., Xeris Pharmaceuticals, Inc., TheraJect, Inc., Burrard Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stabilitech and Silk Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Stabilitech, https://www.bouncewatch.com/company/stabilitech, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout